# Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

> **NCT07238400** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Eplerenone 100 mg daily
- **DRUG:** Chlorthalidone 25 mg daily
- **DRUG:** Potassium Placebo
- **DRUG:** Potassium Chloride

## Key facts

- **NCT ID:** NCT07238400
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2029-03-16
- **Final completion:** 2029-03-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07238400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07238400, "Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07238400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*